Peptide and compounding law · Updated
Which peptides are FDA-approved? The FDA's peptide lists explained
FDA approval belongs to a finished drug product, and only a few peptides have it, among them semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound) and bremelanotide (Vyleesi). The FDA's "category" lists are not approvals. They tell a compounding pharmacy whether it may make a drug from a bulk ingredient while the FDA decides whether that ingredient belongs on its bulks list. As of November 3, 2026, no peptide is on either bulks list; GHK-Cu (other than injectable forms) and vasoactive intestinal peptide are in 503A Category 1; kisspeptin-10 is in 503A Category 2; BPC-157, TB-500 and fifteen others sit in a "nominated but withdrawn" table; and a separate HHS draft policy of October 30, 2026 names six peptides it does not intend to enforce against in 503A compounding. Each list has its own date, and each changes without notice.
| List | What it means for a compounder | Peptides on it | Last updated |
|---|---|---|---|
| FDA-approved drugs (Drugs@FDA) | An approved product may be dispensed on a prescription. A drug that is a component of an approved drug may also be used in 503A compounding | Semaglutide, tirzepatide, bremelanotide and others | Updated daily |
| 503A bulks list (21 CFR 216.23) | A 503A pharmacy may compound from these ingredients | None. Six substances, no peptides | Last amended February 19, 2019 (84 FR 4710) |
| 503A Category 1 (FDA list) | Under evaluation. The FDA does not intend to act against a pharmacy using one, if the interim policy's conditions are met | GHK-Cu (except for injectable routes of administration); vasoactive intestinal peptide | May 14, 2026 |
| 503A Category 2 (FDA list) | The FDA has identified "significant safety risks" in compounding with the substance. No enforcement discretion | Kisspeptin-10 (since September 29, 2023) | May 14, 2026 |
| 503A Category 3 (FDA list) | Nominated "without adequate support" for the FDA to evaluate. No enforcement discretion | Peptides on it include GHRP-2, GHRP-6, cibinetide (ARA-290), mechano growth factor (MGF) and thymulin acetate | May 14, 2026 |
| "Nominated but withdrawn" (FDA safety-risk page) | Formerly Category 2; the nominations were withdrawn. In no category, so no interim-policy route | 17 entries, including BPC-157, TB-500, KPV, MOTS-c, Semax, epitalon, CJC-1295, ipamorelin and GHK-Cu (injectable) | April 22, 2026 |
| 503B bulks list (FDA list) | An outsourcing facility may compound from these ingredients | None. Five substances, no peptides | May 16, 2024 |
| 503B Category 2 (FDA safety-risk page) | Significant safety risks under the 503B interim policy | GHRP-2 (injectable and nasal; its other routes are in 503B Category 1), GHRP-6, ipamorelin acetate (all since September 29, 2023) | April 22, 2026 (503B category list: March 21, 2025) |
| HHS Appendix A (91 FR 68526; HHS policy) | Draft. HHS does not intend to take enforcement action against 503A compounding that meets the policy's conditions. Not 503B | BPC-157, epitalon, KPV, MOTS-c, Semax, TB-500 | October 30, 2026 |
| Peptide | FDA's 503A lists | 503B Category 2? | HHS Appendix A (draft)? |
|---|---|---|---|
| BPC-157 | Nominated but withdrawn (Category 2 from September 29, 2023) | No | Yes |
| TB-500 | Nominated but withdrawn (Category 2 from September 29, 2023) | No | Yes |
| KPV, MOTS-c, Semax, epitalon | Nominated but withdrawn | No | Yes |
| GHK-Cu | Category 1 except injectable routes; the injectable form is in the withdrawn table | No | No |
| Ipamorelin | Nominated but withdrawn | Yes, since September 29, 2023 | No |
| CJC-1295, AOD-9604, melanotan II, thymosin alpha-1, selank, emideltide (DSIP), LL-37 | Nominated but withdrawn | No (thymosin alpha-1 is in 503B Category 3) | No |
| Kisspeptin-10 | Category 2, since September 29, 2023 | No | No |
| GHRP-2, GHRP-6 | Category 3 | Yes, since September 29, 2023 (GHRP-2 for injectable and nasal routes only; its other routes are in 503B Category 1) | No |
| Vasoactive intestinal peptide | Category 1 | No | No |
| Semaglutide, tirzepatide | FDA-approved drugs; compounding limited by the copy rules | Not on the 503B bulks list; FDA proposed on May 1, 2026 not to add them (not final) | No |
FDA approval and the category lists are different things
The FDA approves products, not molecules. A drug company files a new drug application for a specific product, and the approval covers that product, its labeled uses and its maker (21 U.S.C. 355). Approved peptide drugs include semaglutide, tirzepatide and bremelanotide; they are listed in the FDA's Drugs@FDA database, which is the place to check any other name. More on them in Are peptides legal?
Compounded drugs are never FDA-approved, wherever their ingredient sits on a list. In the FDA's words, "compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed" (FDA, October 1, 2026). The category lists answer a narrower question: may a pharmacy use this bulk ingredient while the FDA decides whether to list it? A clinic or website that calls a compounded peptide "FDA-approved" because its ingredient is in Category 1 is misstating the law.
How a peptide ingredient becomes usable in compounding
A pharmacy compounding under section 503A, for an identified patient on a valid prescription, may use a bulk ingredient only if it has a USP or National Formulary monograph, is a component of an FDA-approved drug, or appears on the FDA's 503A bulks list (21 U.S.C. 353a(b)(1)(A)). An outsourcing facility under section 503B may use a bulk ingredient only if it is on the 503B bulks list, the FDA's list of substances for which there is a "clinical need", or if the drug is on the FDA's shortage list when it is compounded and distributed (21 U.S.C. 353b(a)(2)).
Neither bulks list holds a peptide. The 503A list at 21 CFR 216.23 has six substances, mostly for topical use, and was last amended in 2019. The 503B list has five. Every other route for a compounded peptide runs through the FDA's interim categories or, since October 30, 2026, through HHS's draft policy. The difference between the two pathways is set out in 503A vs 503B.
Categories 1, 2 and 3
While it builds the bulks lists, the FDA sorts nominated ingredients into three categories under its interim policies. Its definitions: Category 1 substances "may be eligible for inclusion on the 503A bulks list"; Category 2 substances were "nominated with sufficient supporting information to permit FDA to evaluate them" and the FDA has identified significant safety risks in compounding with them; Category 3 substances "may be eligible for inclusion on the 503A bulks list but were nominated with insufficient supporting information for FDA to evaluate them" (FDA 503A page, current as of May 14, 2026).
Only Category 1 carries enforcement discretion, and only with conditions. The FDA's page says bulk ingredients "must be accompanied by a valid certificate of analysis" and "must have been manufactured by an establishment registered with FDA under section 510". Category 2 and Category 3 give a pharmacy nothing to rely on.
The categories are closed to newcomers. Since January 7, 2025, "the agency does not intend to place bulk drug substances nominated on or after January 7, 2025, into these categories". A peptide that was never nominated before that date has no category route at all; it would need a monograph, an approved drug or a place on the bulks list by rulemaking.
The "nominated but withdrawn" table
The FDA keeps a second table on its safety-risk page for substances "previously in category 2 of the interim policies" whose nominations "were withdrawn by the nominators". As of April 22, 2026 it has 17 entries: AOD-9604, BPC-157, cathelicidin LL-37, CJC-1295, dihexa acetate, emideltide (DSIP), epitalon, GHK-Cu (injectable), ipamorelin acetate, KPV, pegylated mechano growth factor, melanotan II, MOTS-c, selank acetate, Semax, thymosin alpha-1 and TB-500 (FDA safety-risk page). Twelve of them, BPC-157 and TB-500 among them, came out of Category 2 in April 2026.
Leaving Category 2 this way is not a promotion. A withdrawn substance is in no category, so the interim policy's enforcement discretion does not reach it, and the FDA kept each entry's safety statement on the page. Some readers took the April 2026 change as the FDA clearing these peptides. It did not; the later route for six of them came from HHS, not from the FDA's lists. See Is BPC-157 legal? and Is TB-500 legal?
The 503B side
Outsourcing facilities have their own category list, last updated March 21, 2025, and the FDA stopped categorizing new 503B nominations on the same January 7, 2025 date (FDA 503B category list). Three peptides are in 503B Category 2: GHRP-2 (for injectable and nasal routes), GHRP-6 and ipamorelin acetate, all since September 29, 2023. That matters to clinics because office stock, meaning drugs kept on hand rather than dispensed for a named patient, generally comes from 503B outsourcing facilities.
The GLP-1s are the other 503B story. On May 1, 2026 the FDA proposed not to put semaglutide, tirzepatide or liraglutide on the 503B bulks list (91 FR 23431). Comments closed July 30, 2026, and no final notice had been published as of November 3, 2026. See FDA's proposal on the 503B list and Compounded tirzepatide and semaglutide.
HHS's Appendix A is a separate list
On October 30, 2026 HHS, not the FDA, published a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (91 FR 68526). Its Appendix A names six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 (HHS policy). It does not move them into any FDA category and does not add them to the bulks list. It covers 503A compounding for individual patients under its conditions, not 503B, and the notice says the policy "is not binding on HHS or the public". Comments are open until about November 13, 2026.
So a peptide can sit in the FDA's withdrawn table and in HHS's Appendix A at the same time. The two lists answer different questions, issued by different parts of the same department.
Reading the lists before you rely on them
- Check the date on each list, not the date on the article that cites it. The 503A category list, the 503B category list, the safety-risk page and the bulks lists each carry their own.
- Read the route. GHK-Cu is in Category 1 "except for injectable routes of administration"; the injectable form is in the withdrawn table. GHRP-2's 503B Category 2 entry is for injectable and nasal routes; its other routes are in 503B Category 1.
- Match the exact name and salt. A supplier's "TB-500" or "ipamorelin" must be the substance the list or policy names.
- Confirm the pathway. A 503A list or policy does not help an outsourcing facility, and a 503B list does not help a patient-specific pharmacy.
- Ask for the certificate of analysis and the manufacturer's FDA registration; both are conditions for Category 1 and for the HHS policy.
- Check your state. In North Carolina a pharmacy may dispense a compounded drug only on a valid prescription, may not offer compounded drugs to others for resale, and may supply office-use compounds only as federal law allows (21 NCAC 46 .2801).
Common questions
Which peptides are FDA-approved?
Only finished drug products are approved. Peptide drugs with FDA approval include semaglutide (Ozempic, Rybelsus, Wegovy), tirzepatide (Mounjaro, Zepbound) and bremelanotide (Vyleesi). BPC-157, TB-500 and the other peptides common in wellness clinics are not in any approved drug. Check a specific name in the FDA's Drugs@FDA database.
Is a Category 1 peptide FDA-approved?
No. Category 1 means the FDA is still evaluating whether the ingredient belongs on the 503A bulks list, and in the meantime does not intend to act against a pharmacy that compounds with it under the interim policy's conditions. The compounded product is not approved.
What does Category 2 mean?
The FDA has identified significant safety risks in compounding with the ingredient. Category 2 carries no enforcement discretion. As of May 14, 2026, kisspeptin-10 is the peptide in 503A Category 2; GHRP-2 (for injectable and nasal routes; its other routes are in 503B Category 1), GHRP-6 and ipamorelin are in 503B Category 2.
Did the FDA approve BPC-157 when it left Category 2?
No. Its nominators withdrew it, and in April 2026 the FDA moved it to a "nominated but withdrawn" table that places it in no category. The route for BPC-157 since October 30, 2026 is HHS's draft enforcement-discretion policy, which is limited to 503A compounding under its conditions.
Can a peptide be added to Category 1 now?
Not through a new nomination. The FDA stopped placing newly nominated substances into categories on January 7, 2025. A substance nominated after that date waits for the FDA to decide on the bulks list itself.
How often do these lists change?
Without a schedule. In 2026 alone the FDA changed the withdrawn table in April, restored GHK-Cu to Category 1 in May, proposed keeping the GLP-1s off the 503B list in May, and HHS published its peptide policy in October. Each list shows its own date; check it before you rely on it.
Update log
- November 17, 2026. Corrected: the FDA's 503B category list (updated March 21, 2025) also places GHRP-2 in Category 1 for routes other than injectable and nasal, and places thymosin alpha-1 in Category 3; the first table's 503B Category 2 row, the second table's GHRP-2 and thymosin alpha-1 rows, the "Read the route" sentence and the Category 2 FAQ now say so.
- November 3, 2026. Published. The FDA's 503A category list (May 14, 2026), 503B category list (March 21, 2025), 503A page and safety-risk page (April 22, 2026) read at the source November 3, 2026; Federal Register checked for a final 503B notice (none). The HHS appendix as confirmed November 2, 2026.
Sources
- FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category list, updated May 14, 2026)
- FDA, Bulk Drug Substances Used in Compounding Under Section 503A (current as of May 14, 2026)
- FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (current as of April 22, 2026)
- FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503B (category list, updated March 21, 2025)
- FDA, 503B Bulk Drug Substances List
- 21 CFR 216.23 (503A bulks list)
- 21 U.S.C. 353a (section 503A)
- 21 U.S.C. 353b (section 503B)
- 21 U.S.C. 355 (new drugs)
- HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, 91 FR 68526 (Oct. 30, 2026)
- HHS, the policy with Appendix A (hhs.gov PDF)
- FDA, proposal not to include semaglutide, tirzepatide and liraglutide on the 503B Bulks List, 91 FR 23431 (May 1, 2026)
- FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (current as of October 1, 2026)
- FDA, Drugs@FDA database
- 21 NCAC 46 .2801 (North Carolina compounding rule; Cornell LII copy)
Related
Not sure which list your peptide program relies on?
DPS Law advises clinics, physicians and pharmacies on North Carolina and federal compounding law. For another state's pharmacy or medical board rules, talk to a lawyer licensed in that state.